Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.82
VIVO's Cash to Debt is ranked lower than
68% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.70 vs. VIVO: 0.82 )
Ranked among companies with meaningful Cash to Debt only.
VIVO' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 14.28 Max: No Debt
Current: 0.82
Equity to Asset 0.66
VIVO's Equity to Asset is ranked higher than
58% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. VIVO: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
VIVO' s Equity to Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.78 Max: 0.92
Current: 0.66
0.35
0.92
Interest Coverage 1311.65
VIVO's Interest Coverage is ranked higher than
68% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.98 vs. VIVO: 1311.65 )
Ranked among companies with meaningful Interest Coverage only.
VIVO' s Interest Coverage Range Over the Past 10 Years
Min: 210.01  Med: 10000.00 Max: 9999.99
Current: 1311.65
210.01
9999.99
F-Score: 6
Z-Score: 7.61
M-Score: -2.93
WACC vs ROIC
9.35%
27.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 29.12
VIVO's Operating margin (%) is ranked higher than
96% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. VIVO: 29.12 )
Ranked among companies with meaningful Operating margin (%) only.
VIVO' s Operating margin (%) Range Over the Past 10 Years
Min: 24.79  Med: 28.63 Max: 32.9
Current: 29.12
24.79
32.9
Net-margin (%) 18.36
VIVO's Net-margin (%) is ranked higher than
90% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.63 vs. VIVO: 18.36 )
Ranked among companies with meaningful Net-margin (%) only.
VIVO' s Net-margin (%) Range Over the Past 10 Years
Min: 16.8  Med: 18.93 Max: 22.09
Current: 18.36
16.8
22.09
ROE (%) 21.43
VIVO's ROE (%) is ranked higher than
92% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.04 vs. VIVO: 21.43 )
Ranked among companies with meaningful ROE (%) only.
VIVO' s ROE (%) Range Over the Past 10 Years
Min: 19.36  Med: 22.86 Max: 25.78
Current: 21.43
19.36
25.78
ROA (%) 18.03
VIVO's ROA (%) is ranked higher than
97% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. VIVO: 18.03 )
Ranked among companies with meaningful ROA (%) only.
VIVO' s ROA (%) Range Over the Past 10 Years
Min: 15.86  Med: 20.40 Max: 22.5
Current: 18.03
15.86
22.5
ROC (Joel Greenblatt) (%) 64.98
VIVO's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.88 vs. VIVO: 64.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VIVO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 56.1  Med: 71.90 Max: 89.27
Current: 64.98
56.1
89.27
Revenue Growth (3Y)(%) 3.60
VIVO's Revenue Growth (3Y)(%) is ranked lower than
52% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. VIVO: 3.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VIVO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 2.4  Med: 9.20 Max: 23
Current: 3.6
2.4
23
EBITDA Growth (3Y)(%) 2.80
VIVO's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. VIVO: 2.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VIVO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.4  Med: 6.50 Max: 22.6
Current: 2.8
-2.4
22.6
EPS Growth (3Y)(%) 1.80
VIVO's EPS Growth (3Y)(%) is ranked higher than
55% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.10 vs. VIVO: 1.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VIVO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -23.2  Med: 8.50 Max: 34.8
Current: 1.8
-23.2
34.8
» VIVO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

VIVO Guru Trades in Q2 2015

Jim Simons 1,204,676 sh (+45.99%)
John Keeley 101,460 sh (+9.67%)
Paul Tudor Jones 30,225 sh (+3.78%)
Mario Gabelli 139,000 sh (unchged)
Joel Greenblatt 271,315 sh (-4.15%)
Chuck Royce 139,300 sh (-35.15%)
» More
Q3 2015

VIVO Guru Trades in Q3 2015

Jim Simons 1,391,255 sh (+15.49%)
John Keeley 111,615 sh (+10.01%)
Mario Gabelli 140,000 sh (+0.72%)
Paul Tudor Jones 27,713 sh (-8.31%)
Joel Greenblatt 182,068 sh (-32.89%)
Chuck Royce 53,600 sh (-61.52%)
» More
Q4 2015

VIVO Guru Trades in Q4 2015

Jim Simons 1,574,576 sh (+13.18%)
Mario Gabelli 140,000 sh (unchged)
Chuck Royce 48,300 sh (-9.89%)
John Keeley 96,115 sh (-13.89%)
Paul Tudor Jones 18,218 sh (-34.26%)
Joel Greenblatt 86,476 sh (-52.50%)
» More
Q1 2016

VIVO Guru Trades in Q1 2016

Paul Tudor Jones 39,675 sh (+117.78%)
Joel Greenblatt 171,177 sh (+97.95%)
Jim Simons 1,710,600 sh (+8.64%)
Mario Gabelli 140,000 sh (unchged)
Chuck Royce 48,300 sh (unchged)
John Keeley 89,275 sh (-7.12%)
» More
» Details

Insider Trades

Latest Guru Trades with VIVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:MYGN, TSE:4544, SZSE:300463, NAS:CPHD, NAS:NEOG, SZSE:300439 » details
Traded in other countries:MR4.Germany,
Meridian Bioscience Inc is an integrated life science company. It is engaged in development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases.

Meridian Bioscience Inc was incorporated in Ohio in 1976. The Company is an integrated life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers; and the contract development and manufacture of proteins and other biologicals under cGMP conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Its segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the countries comprising North, Central and South America (the Americas); Europe, Middle East and Africa (EMEA); and other countries outside of the Americas and EMEA (rest of the world, or ROW). In the Diagnostics Segment, its testing platforms include: Isothermal DNA Amplification (illumigene brand); Rapid Immunoassay (TRU, ImmunoCard and ImmunoCard STAT! brands); and Enzyme-linked Immunoassay (Premier brand). Its product portfolio includes over 140 diagnostic tests and transport media, and is marketed to acute care hospitals, reference laboratories and outpatient clinics in over 70 countries around the world. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Ratios

vs
industry
vs
history
P/E(ttm) 23.16
VIVO's P/E(ttm) is ranked higher than
62% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.05 vs. VIVO: 23.16 )
Ranked among companies with meaningful P/E(ttm) only.
VIVO' s P/E(ttm) Range Over the Past 10 Years
Min: 19.27  Med: 27.45 Max: 48.85
Current: 23.16
19.27
48.85
Forward P/E 20.66
VIVO's Forward P/E is ranked lower than
51% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. VIVO: 20.66 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.16
VIVO's PE(NRI) is ranked higher than
62% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.16 vs. VIVO: 23.16 )
Ranked among companies with meaningful PE(NRI) only.
VIVO' s PE(NRI) Range Over the Past 10 Years
Min: 19.2  Med: 27.31 Max: 49
Current: 23.16
19.2
49
Price/Owner Earnings (ttm) 23.75
VIVO's Price/Owner Earnings (ttm) is ranked higher than
61% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.47 vs. VIVO: 23.75 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
VIVO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 17.82  Med: 31.04 Max: 53.57
Current: 23.75
17.82
53.57
P/B 4.82
VIVO's P/B is ranked lower than
67% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. VIVO: 4.82 )
Ranked among companies with meaningful P/B only.
VIVO' s P/B Range Over the Past 10 Years
Min: 4.12  Med: 6.23 Max: 11.73
Current: 4.82
4.12
11.73
P/S 4.24
VIVO's P/S is ranked lower than
60% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. VIVO: 4.24 )
Ranked among companies with meaningful P/S only.
VIVO' s P/S Range Over the Past 10 Years
Min: 3.26  Med: 5.33 Max: 10.9
Current: 4.24
3.26
10.9
PFCF 21.85
VIVO's PFCF is ranked higher than
61% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.05 vs. VIVO: 21.85 )
Ranked among companies with meaningful PFCF only.
VIVO' s PFCF Range Over the Past 10 Years
Min: 17.53  Med: 32.59 Max: 163.55
Current: 21.85
17.53
163.55
POCF 19.86
VIVO's POCF is ranked lower than
53% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.45 vs. VIVO: 19.86 )
Ranked among companies with meaningful POCF only.
VIVO' s POCF Range Over the Past 10 Years
Min: 15.25  Med: 26.39 Max: 49.37
Current: 19.86
15.25
49.37
EV-to-EBIT 14.77
VIVO's EV-to-EBIT is ranked higher than
66% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.15 vs. VIVO: 14.77 )
Ranked among companies with meaningful EV-to-EBIT only.
VIVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.9  Med: 17.70 Max: 34.9
Current: 14.77
11.9
34.9
EV-to-EBITDA 13.55
VIVO's EV-to-EBITDA is ranked higher than
57% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.21 vs. VIVO: 13.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
VIVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.7  Med: 15.80 Max: 31.1
Current: 13.55
10.7
31.1
PEG 3.56
VIVO's PEG is ranked lower than
59% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.63 vs. VIVO: 3.56 )
Ranked among companies with meaningful PEG only.
VIVO' s PEG Range Over the Past 10 Years
Min: 0.98  Med: 3.09 Max: 19.66
Current: 3.56
0.98
19.66
Shiller P/E 24.06
VIVO's Shiller P/E is ranked higher than
81% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.91 vs. VIVO: 24.06 )
Ranked among companies with meaningful Shiller P/E only.
VIVO' s Shiller P/E Range Over the Past 10 Years
Min: 21.25  Med: 43.34 Max: 134.75
Current: 24.06
21.25
134.75
Current Ratio 6.03
VIVO's Current Ratio is ranked higher than
83% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. VIVO: 6.03 )
Ranked among companies with meaningful Current Ratio only.
VIVO' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 5.42 Max: 10.21
Current: 6.03
1.85
10.21
Quick Ratio 4.06
VIVO's Quick Ratio is ranked higher than
73% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. VIVO: 4.06 )
Ranked among companies with meaningful Quick Ratio only.
VIVO' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 3.64 Max: 8.77
Current: 4.06
1.06
8.77
Days Inventory 195.45
VIVO's Days Inventory is ranked lower than
87% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. VIVO: 195.45 )
Ranked among companies with meaningful Days Inventory only.
VIVO' s Days Inventory Range Over the Past 10 Years
Min: 130.86  Med: 174.97 Max: 184.53
Current: 195.45
130.86
184.53
Days Sales Outstanding 61.15
VIVO's Days Sales Outstanding is ranked higher than
53% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 61.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
VIVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.91  Med: 56.55 Max: 67.24
Current: 61.15
44.91
67.24
Days Payable 42.10
VIVO's Days Payable is ranked lower than
60% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. VIVO: 42.10 )
Ranked among companies with meaningful Days Payable only.
VIVO' s Days Payable Range Over the Past 10 Years
Min: 25.32  Med: 33.01 Max: 45.39
Current: 42.1
25.32
45.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.12
VIVO's Dividend Yield is ranked higher than
95% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. VIVO: 4.12 )
Ranked among companies with meaningful Dividend Yield only.
VIVO' s Dividend Yield Range Over the Past 10 Years
Min: 1.24  Med: 3.27 Max: 4.96
Current: 4.12
1.24
4.96
Dividend Payout 0.95
VIVO's Dividend Payout is ranked lower than
82% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. VIVO: 0.95 )
Ranked among companies with meaningful Dividend Payout only.
VIVO' s Dividend Payout Range Over the Past 10 Years
Min: 0.26  Med: 0.77 Max: 2.9
Current: 0.95
0.26
2.9
Dividend Growth (3y) 1.70
VIVO's Dividend Growth (3y) is ranked lower than
67% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. VIVO: 1.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
VIVO' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0.9  Med: 14.00 Max: 37.5
Current: 1.7
0.9
37.5
Forward Dividend Yield 4.12
VIVO's Forward Dividend Yield is ranked higher than
91% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.26 vs. VIVO: 4.12 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.42
VIVO's Yield on cost (5-Year) is ranked higher than
85% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. VIVO: 4.42 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
VIVO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.34  Med: 3.52 Max: 5.34
Current: 4.42
1.34
5.34
3-Year Average Share Buyback Ratio -0.50
VIVO's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.30 vs. VIVO: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VIVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.8  Med: -0.70 Max: -0.3
Current: -0.5
-5.8
-0.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 20.66
VIVO's Price/Net Current Asset Value is ranked lower than
82% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. VIVO: 20.66 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VIVO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 6.79  Med: 11.30 Max: 66.58
Current: 20.66
6.79
66.58
Price/Tangible Book 11.23
VIVO's Price/Tangible Book is ranked lower than
79% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. VIVO: 11.23 )
Ranked among companies with meaningful Price/Tangible Book only.
VIVO' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.6  Med: 8.84 Max: 13.76
Current: 11.23
3.6
13.76
Price/Projected FCF 1.73
VIVO's Price/Projected FCF is ranked higher than
63% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. VIVO: 1.73 )
Ranked among companies with meaningful Price/Projected FCF only.
VIVO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.17  Med: 2.58 Max: 4.53
Current: 1.73
1.17
4.53
Price/DCF (Earnings Based) 1.87
VIVO's Price/DCF (Earnings Based) is ranked higher than
60% of the 15 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. VIVO: 1.87 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.79
VIVO's Price/Median PS Value is ranked higher than
66% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. VIVO: 0.79 )
Ranked among companies with meaningful Price/Median PS Value only.
VIVO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 0.87 Max: 1.94
Current: 0.79
0.12
1.94
Price/Peter Lynch Fair Value 3.72
VIVO's Price/Peter Lynch Fair Value is ranked lower than
80% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.37 vs. VIVO: 3.72 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
VIVO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.61  Med: 1.84 Max: 6.17
Current: 3.72
0.61
6.17
Price/Graham Number 3.40
VIVO's Price/Graham Number is ranked lower than
56% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. VIVO: 3.40 )
Ranked among companies with meaningful Price/Graham Number only.
VIVO' s Price/Graham Number Range Over the Past 10 Years
Min: 2.09  Med: 3.14 Max: 5.45
Current: 3.4
2.09
5.45
Earnings Yield (Greenblatt) (%) 6.78
VIVO's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.40 vs. VIVO: 6.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VIVO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.9  Med: 5.70 Max: 8.4
Current: 6.78
2.9
8.4
Forward Rate of Return (Yacktman) (%) 10.25
VIVO's Forward Rate of Return (Yacktman) (%) is ranked higher than
57% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.36 vs. VIVO: 10.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
VIVO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 10.50 Max: 26.8
Current: 10.25
1.5
26.8

More Statistics

Revenue (TTM) (Mil) $193.7
EPS (TTM) $ 0.84
Beta1.00
Short Percentage of Float13.48%
52-Week Range $16.60 - 21.49
Shares Outstanding (Mil)42.07

Analyst Estimate

Sep16 Sep17
Revenue (Mil $) 202 211
EPS ($) 0.88 0.94
EPS without NRI ($) 0.88 0.94
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for VIVO

Headlines

Articles On GuruFocus.com
The Four Horsemen: Risk, Uncertainty, Price and Value Mar 19 2015 
Guru-Held Stocks Trading At Historical Low P/B Oct 08 2014 
Small-Cap Consensus Picks By The Investing Gurus Jul 25 2014 
13 Stocks Delivering What's Important: Dividend Increases Jan 27 2014 
68 Top Dividend Stocks with Ex-Dividend Date in August 2013 Jul 29 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
16 Best Dividend Paying Healthcare Stocks Sep 03 2012 
15 of the Best Growing Dividend Achievers Jul 30 2012 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 

More From Other Websites
MERIDIAN BIOSCIENCE INC Financials May 14 2016
MERIDIAN BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report May 06 2016
Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q2, 2016 By the Numbers May 04 2016
Nabors Industries Ltd. (NBR) and Two Other Companies Highlight Slow-Escalating Insider Buying May 03 2016
Cincinnati public firm's huge loan part of Fifth Third’s $12B in business credits May 02 2016
MERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition Apr 29 2016
Meridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend,... Apr 28 2016
Meridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend,... Apr 28 2016
Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae Apr 27 2016
Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae Apr 27 2016
Meridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : April 26, 2016 Apr 26 2016
ETF’s with exposure to Meridian Bioscience, Inc. : April 26, 2016 Apr 26 2016
Meridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : April... Apr 25 2016
Meridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : March... Mar 29 2016
Billerica maker of lead diagnostic test Magellan acquired by Meridian for $66M Mar 25 2016
Cincinnati public company makes acquisition Mar 25 2016
Meridian Bioscience Acquires Magellan Diagnostics, Inc. Mar 24 2016
MERIDIAN BIOSCIENCE INC Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 24 2016
Meridian Bioscience Acquires Magellan Diagnostics, Inc. Mar 24 2016
[$$] Meridian Bioscience Stock Could Pause Mar 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)